### Thursday, December 7, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 am</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>7:00 am – 8:00 am</td>
<td><strong>EXHIBIT HALL OPENS</strong> - COFFEE</td>
<td></td>
</tr>
</tbody>
</table>
| 7:00 am – 7:45 am | **Breakfast Session**  
Lecture Title  
Supported by Biomea  
Speaker: Rohit Kulkarni, MD, PhD  
Juan Frias, MD | Product Theater Hall  
EXHIBIT HALL OPENS  
COFFEE |
| 8:00 am – 8:15 am | Welcome & Introduction  
Yehuda Handelsman, MD |                |
| 8:10 am- 8:15 am | Pre-CME Questions  
Session 1  
**Endothelium and Cardiometabolic Disorders**  
Chairs: Vivian A. Fonseca, MD • Derek LeRoith, MD, PhD |                |
| 8:15 am – 9:30 am |  
8:15 am The Effects of RYGB on Cholesterol and Bile Acid Metabolism in Humans  
Bart Staels, PhD  
8:35 am Endothelial-Mesenchymal Transition in Cardiovascular Disease (EndMT)  
Jorge Plutzky, MD  
8:55 am The Role of SGLTx in ACS, A. Fib & Metabolism- A Translational Approach  
Robert J. Chilton, DO  
9:15 am – 9:30 am Panel Discussion and Q&A |                |
| 9:30 am – 10:15 am | ASCVD Epidemiology, Pathophysiology & Management  
Session 2  
Chairs: Ronald M. Krauss, MD • Robert J. Chilton, MD |                |
| 9:30 am | Importance of Cardiovascular Risk Assessment and Multiple Risk Factor Control in Diabetes  
Nathan D. Wong, PhD  
9:50 am Common Molecular Mechanisms Drive Cardiometabolic and Vascular Diseases Outcomes- Clinical Implications  
W. Timothy Garvey, MD  
10:10 am | The Relationships Between HDL Dysfunction, Genetic Very Small LDL, CAC and Insulin Resistance  
Arthur S. Agatston, MD |                |
| 10:30 am – 10:45 am | Panel Discussion and Q&A |                |
| 10:45 am – 11:15 am | REFRESHMENT BREAK at the Exhibit Hall |                |
| 11:15 am – 12:10 pm | Lipidology Toward 2024- Panel Discussion  
Session 3  
Chairs: Erin D. Michos, MD, MHS • Chris K. Guerin, MD |                |
| 11:15 am | The Role of the Mitochondrial/ER Axis in Cholesterol Metabolism and Statin Myopathy  
Lp(a), CETP / BA-CLEAR / Very High HDL  
Panel Discussions and Q&A  
Ronald M. Krauss, MD  
Seth S. Martin, MD, MHS  
Arthur S. Agatston, MD |                |
| 12:10 pm | |                |
| 12:15 pm – 1:00 pm | Concurrent Sessions: **Meet the Experts**  
Ralph A. DeFronzo, MD Insulin Resistance – Intensive Management of DM  
Sierra C/D (Lecture Hall)  
Vivian A. Fonseca, MD DCRM Risk Prediction  
Club  
Jennifer B. Green, MD CKD Emerging Strategies  
Hiro  
Yehuda Handelsman, MD Technology in DM and CRM  
Salon 6AB |                |
| 1:00 pm – 2:00 pm | LUNCH BREAK |                |
| 1:10 pm – 1:55 pm | Lunch Session  
Lecture Title  
Non-CME  
Product Theater Hall  
Speaker |                |
<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session 5</td>
<td>2:00 pm – 2:50 pm</td>
<td>Metabolic Science&lt;br&gt;Genome- Proteome- Phenome &amp; Mendelian Randomization Studies, Elucidating Novel Pathways and Treatments- Clinical Implication in Cardiometabolic Disorders</td>
<td>Christos S. Mantzoros, MD, PhD&lt;br&gt;Rohit Kulkarni, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>2:00 pm</td>
<td>The Role of mRNA Modifications in the Regulation of Metabolism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:40 pm – 2:50 pm</td>
<td>Panel Discussion and Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>Session 6</td>
<td>2:50 pm – 3:40 pm</td>
<td>The Future of HTN&lt;br&gt;Refractory HTN and New Drugs &amp; Procedures in the Future</td>
<td>Norman E. Lepor, MD&lt;br&gt;Keith C. Ferdinand, MD</td>
</tr>
<tr>
<td></td>
<td>2:50 pm</td>
<td>Need for New Agents to Overcome Healthcare Disparity in Hypertension</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:30 pm – 3:40 pm</td>
<td>Panel Discussion and Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>Session 7</td>
<td>3:40 pm – 4:10 pm</td>
<td>DCRM 2.0 – Update and Global Transformation&lt;br&gt;DCRM 2.0 - Diabetes CardioRenal &amp; Metabolic Diseases- Update &amp; Global</td>
<td>Yehuda Handelsman, MD</td>
</tr>
<tr>
<td></td>
<td>3:55 pm – 4:10 pm</td>
<td>Panel Discussion and Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>4:10 pm – 4:40 pm</td>
<td>REFRESHMENT BREAK at the Exhibit Hall</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session 8</td>
<td>5:00 pm – 6:30 pm</td>
<td>Insulin Resistance, Diabetes, and Beyond&lt;br&gt;Brain HDL and Alzheimer's Disease: Toward Therapeutic Applications</td>
<td>Hussein Yassine, MD&lt;br&gt;Peter J. Grant, MD</td>
</tr>
<tr>
<td></td>
<td>5:00 pm</td>
<td>Pulmonary Disease in Diabetes - Another Final Frontier?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5:20 pm</td>
<td>Contemporary Nomenclature of Fatty Liver Disease Impact on Diagnosis and Management</td>
<td>Rohit Loomba, MD, MHSc&lt;br&gt;Matthew R. Weir, MD</td>
</tr>
<tr>
<td></td>
<td>5:40 pm</td>
<td>Vascular Aging in CKD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6:00 pm</td>
<td>Management of Diabetes in Patients with Cancer Addressing Impact of Cancer Therapy</td>
<td>Emily J. Gallagher, MD, PhD&lt;br&gt;Matthew R. Weir, MD</td>
</tr>
<tr>
<td></td>
<td>6:20 pm – 6:35 pm</td>
<td>Panel Discussion and Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>6:35 pm – 7:30 pm</td>
<td>WELCOME &amp; POSTER RECESSION AT EXHIBIT HALL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 pm – 9:15 pm</td>
<td>Dinner CME Symposium&lt;br&gt;Winning The Trifecta of Diabetes, the Heart and Kidney Diseases</td>
<td>Supported by AstraZeneca&lt;br&gt;Muthu Vaduganathan, MD, MPH&lt;br&gt;Vivan A. Fonseca, MD&lt;br&gt;Peter Rossing, MD&lt;br&gt;Muthu Vaduganathan, MD, MPH&lt;br&gt;Matthew R. Weir, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7:30 pm</td>
<td>Introduction &amp; Pre-CME Questions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7:50 pm</td>
<td>Early Intervention in Diabetes Addressing Pathophysiology in Preventing Comorbidities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:10 pm</td>
<td>SGLT2i Effects Across the Spectrum of CKD and Multiple Populations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:30 pm</td>
<td>Impact of SGLT2i on HF Outcomes in Various Populations &amp; the Range of LVEF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:50 pm</td>
<td>Panel Discussion and Q&amp;A: Changing the Trajectory of Heart Failure and CKD, Implementing Guidelines Directed Medical Therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panel: Vivian A. Fonseca, MD • Christian W. Mende, MD • Erin D. Michos, MD, MHS • Peter Rossing, MD • Muthu Vaduganathan, MD, MPH</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderator: Yehuda Handelsman, MD</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
<td>Supporting Company</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>9:10 pm</td>
<td>Concluding Remarks &amp; Post-CME Questions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15 pm</td>
<td>Adjourn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 am</td>
<td>Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 am – 8:00 am</td>
<td>EXHIBIT HALL OPENS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 am – 7:45 am</td>
<td>Breakfast Session</td>
<td>Non-CME</td>
<td>Product Theater Hall</td>
</tr>
<tr>
<td></td>
<td>Lecture Title</td>
<td>Supported by Bayer</td>
<td></td>
</tr>
<tr>
<td>8:00 am – 8:15 am</td>
<td>Summary of Day 1 and Pre-CME Questions</td>
<td>Zachary T. Bloomgarden, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session 9</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:15 am</td>
<td>Women's Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:15 am – 9:05 am</td>
<td>Chairs: Ania M. Jastrenboff, MD • Pam R. Taub</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:15 am</td>
<td>Infertility, Assisted Reproductive Technology, and Cardiovascular Risk</td>
<td>Erin D. Michos, MD, MHS</td>
<td></td>
</tr>
<tr>
<td>8:35 am</td>
<td>Sex Differences in Cardiovascular Risk Associated with Pre, Newly Diagnosed, and Undiagnosed- Diabetes</td>
<td>Vivian A. Fonseca, MD</td>
<td></td>
</tr>
<tr>
<td>8:55 am – 9:05 am</td>
<td>Panel Discussion and Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session 10</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:05 am – 10:20 am</td>
<td>The Multiple Faces of Insulin Resistance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:05 am</td>
<td>Chairs: Ralph A. DeFronzo, MD • Peter J. Grant, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:05 am</td>
<td>Insulin Resistance in T2DM: Whole Body, Organ, Cellular, and Molecular Pathogenesis</td>
<td>Ralph A. DeFronzo, MD</td>
<td></td>
</tr>
<tr>
<td>9:25 am</td>
<td>Insulin Resistance and Myocardial Energy Metabolism: Implications for Therapy</td>
<td>E. Dale Abel, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>9:45 am</td>
<td>Which Comes First: Insulin Resistance or Obesity?</td>
<td>Samuel Klein, MD</td>
<td></td>
</tr>
<tr>
<td>10:05 am – 10:20 am</td>
<td>Panel Discussion and Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20 am – 10:50 am</td>
<td>REFRESHMENT BREAK at the Exhibit Hall</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session 11</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:50 am – 12:05 pm</td>
<td>Progress in Pediatric Obesity and T2D: New and Advanced Treatments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:50 am</td>
<td>Chairs: Sonia Caprio, MD • Alan R. Sinaiko, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:50 am</td>
<td>GLP-1 RA for the Treatment of Youth Onset Obesity and T2D: From Fantasy to Reality</td>
<td>Silva Arslanian, MD</td>
<td></td>
</tr>
<tr>
<td>11:10 am</td>
<td>Achieving Metabolic Homeostasis in Youth with Obesity, Prediabetes/T2D and NAFLD, Using Semaglutide 2.4 mg.</td>
<td>Sonia Caprio, MD</td>
<td></td>
</tr>
<tr>
<td>11:30 am</td>
<td>Novel Treatments on the Horizon for Youth with Obesity, Fatty Liver &amp; T2D</td>
<td>Rohit Kohli MBBS, MS</td>
<td></td>
</tr>
<tr>
<td>11:50 am – 12:05 pm</td>
<td>Panel Discussion and Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:05 pm – 1:05 pm</td>
<td>LUNCH BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 pm – 1:00 pm</td>
<td>Lunch Session</td>
<td>Non-CME</td>
<td>Product Theater Hall</td>
</tr>
<tr>
<td></td>
<td>Mounjaro® (tirzepatide) Product Theater</td>
<td>Supported by Lilly</td>
<td></td>
</tr>
<tr>
<td>1:05 pm – 2:20 pm</td>
<td>Joint Session with Metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:05 pm</td>
<td>Chairs: Christos S. Mantzoros, MD, PhD • Tracey L. Mclaughlin, MD, MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:05 pm</td>
<td>Vascular Mineralocorticotoid Receptors, Vascular Insulin Sensitivity in Cardiometabolic Disorders: From Physiology to Clinical Relevance</td>
<td>Michael A. Hill, PhD</td>
<td></td>
</tr>
<tr>
<td>1:25 pm</td>
<td>Metabolic Surgery Important Role in the Comprehensive Management of Metabolic Diseases</td>
<td>Geltrude Mingrone, M.D., Ph.D</td>
<td></td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Cardiorenal Protection with SGLT2 Inhibitors: From Physiology to Clinical Outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Session 13
2:20 pm – 3:35 pm
Non-CME: A Glimpse into the Future - What’s in the Pipeline?
Chairs: Ralph A. DeFronzo, MD • Christos S. Mantzoros, MD, PhD

2:20 pm Regeneron
2:35 pm Esperion
2:50 pm Corcept
3:05 pm – 3:20 pm Panel Discussion and Q&A

3:20 pm – 4:35 pm Refreshment Break at the Exhibit Hall

3:40 pm – 4:25 pm Reception Session
Non-CME Education
Product Theater Hall

3:40 pm – 3:45 pm Supported by BI

Speaker: Pamela Kushner, MD
David Cherney, MD
Yehuda Handelsman, MD

Session 14
4:35 pm – 6:15 pm Contemporary Management of Diabetes
Chairs: George Grunberger MD • Paul S. Jellinger, MD

4:35 pm Molecular Mechanisms by Which Glucagon Regulates Hepatic Mitochondrial Oxidation and Gluconeogenesis – Implications for Dual and Triple GLP-1 Analogs
Gerald I. Shulman, MD, PhD

4:55 pm Incretins in Diabetes- The New, The Newest and the Future
Richard E. Pratley, MD

5:15 pm Application of CGM to Diabetes Prevention
Tracey L. McLaughlin, MD, MS

5:35 pm Overcoming Clinical Inertia: The COORDINATE- Diabetes Example
Jennifer B. Green, MD

5:55 pm – 6:15 pm Faculty Panel Discussion and Q&A
### SATURDAY, DECEMBER 9, 2023

**7:00 am**
Registration

**7:00 am – 7:45 am**
**Breakfast Session**
- Non-CME Lecture Title
- Supported by **Corcept**

**8:00 am – 8:05 am**
**Oral Abstract Winner Award Presentation**
Zachary Bloomgarden, MD

**8:05 am – 8:20 am**
Summary of Day 2 and Pre-CME Questions
Zachary T. Bloomgarden, MD

**Session 15**
**Cardiomyopathy & Heart Failure - Panel Session**
Chairs: Nikolaus Marx, MD • Mikhail N. Kosiborod, MD

- **8:20 am**
  - Contemporary Approach to Cardiac Amyloidosis
  - Classification & Reclassification of (Pre-)Heart Failure Stages Using Cardiac Biomarkers
  - The Role of Diuretics in Heart Failure
  - Management of Heart Failure: Bridging the Gap Between Evidence and Practice
  - Discussions and Q&A

**10:00 am**
**REFRESHMENT BREAK**

**Session 16**
**CVOT & Guidelines**
Chairs: Peter J. Grant, MD • Matthew R. Weir, MD

- **10:10 am**
  - CVOTs Update

- **10:30 am**
  - 2023 ESC Diabetes and Cardiovascular Disease Guidelines

- **10:50 am**
  - Panel Discussion and Q&A

**Session 17**
**Gerald Reaven Distinguished Leader in Insulin Resistance 2023 Award**

- **11:00 am**
  - Award Presentation by Peter J. Grant, MD • Samuel Klein, MD

- **11:05 am**
  - Insulin Resistance and its outcomes in T2DM: A Historical and Epidemiological Perspective

**11:35 am – 11:45 am**
Q&A

**11:45 am – 12:45 pm**
**LUNCH & CHECK-OUT BREAK**
### Session 18: Fat Mass and Adipocyte

**12:45 pm – 1:35 pm**  
Chairs: Richard E. Pratley, MD • Bart Staels, PhD

- **12:45 pm**  
The Role of Relative Fat Mass - RFM vs. BMI Predicting T2D, Heart Failure and CVD & Predicting T2D, Heart Failure and CVD  
Richard N. Bergman, PhD

- **1:05 pm**  
GIP-RA Action in the Adipocyte  
Philipp E. Scherer, PhD

- **1:25 pm – 1:35 pm**  
Panel Discussion and Q&A

---

### Session 19: Contemporary Approach to Obesity - Panel Session

**1:35 pm – 2:50 pm**  
Chairs: Samuel Klein, MD • W. Timothy Garvey, MD

- **1:35 pm**  
Nutrient-Stimulated Hormone-Based Therapies for Obesity Treatment: Clinical Application and Pipeline  
Ania M. Jastreboff, MD, PhD

- **1:35 pm**  
Diets, Calorie restrictions vs intermittent fasting addressing the energy balance model  
Eric Ravussin, PhD

- **1:35 pm**  
Weight and Weight Changes Impact on CV Risk  
Neha J. Pagidipati, MD, MPH

- **1:35 pm**  
Discussions and Q&A: Does the Availability of Effective Pharmacotherapy to Treat Obesity Negates the Need for the Other Treatment Options?

**2:55 pm**

### Session 20: Not All Diabetes – is Type 2 DM

**3:10 pm – 4:00 pm**  
Chairs: Paul Zimmet, MD • Zachary T. Bloomgarden, MD

- **3:10 pm**  
Diabetes Secondary to Pancreatitis  
Mark O. Goodarzi, MD, PhD

- **3:30 pm**  
2023 Prevention and Management of T1D- the New Reality  
George Grunberger, MD

- **3:50 pm – 4:00 pm**  
Panel Discussion and Q&A

---

### Session 21: ASCVD Imaging - Panel Session

**4:00 pm – 5:00 pm**  
Chairs: Matthew J. Budoff, MD • Norman E. Lepor, MD

- **4:00 pm**  
Imaging in Predicting Subacute Atherosclerosis  
Matthew J. Budoff, MD • Michael J. Blaha, MD, MPH

- **4:00 pm**  
CTA in Predicting Survival- the CONFIRM Registry

- **4:00 pm**  
Association of Coronary Artery Calcium & Spine Bone Density

- **4:00 pm**  
Comparing Plaques in Patients with & without Statins +/- DM

- **4:00 pm**  
Discussions and Q&A

**5:00 pm**

### Session 22: Concurrent Sessions: Clinical Workshop

**5:00 pm – 6:00 pm**  

- **Lipids**  
Paul S. Jellinger, MD & Paul D. Rosenblit, MD, PhD

- **Diabetes**  
George Grunberger, MD

- **HTN/CKD**  
Christian W. Mende, MD

---

**6:00 pm**  
Adjourn